



**SK Life Science Labs, a Subsidiary of SK Biopharmaceuticals, Announces Publication of a Promising New Cancer-Targeting Compound for Specific Mutations**

*The identification and use of several potent compounds demonstrate their potential in cancer treatments*

**KING OF PRUSSIA, Pa., January 31, 2025** – SK Life Science Labs, a subsidiary of SK Biopharmaceuticals, Co., Ltd., a global biotech focused on the research, development, and commercialization of treatments for disorders of the central nervous system (CNS) and cancer, has published full findings on the discovery and characterization of SMARCA2 heterobifunctional degraders, as well as detailed results of in vivo efficacy in a solid tumor xenograft model, in the January 23, 2025 issue of the Journal of Medicinal Chemistry. The findings demonstrate selective SMARCA2 degradation, which leads to targeted growth inhibition of SMARCA4 mutant cancer cell lines.

“We are excited to share these data with our SMARCA2 selective lead compounds, which demonstrate potent selective degradation of SMARCA2 in vivo, and selective growth inhibition of SMARCA4 mutated cancer cells,” said Helai Mohammad, Ph.D., Chief Scientific Officer, SK Life Science Labs and co-author of this manuscript. “These findings show that SMARCA2 degradation may be a viable approach for treating SMARCA4-mutated cancers, including non-small cell lung carcinoma, colon adenocarcinoma, bladder, and endometrial cancer.”

The published data showcase the team’s strategy for the optimization of SMARCA2 degraders to enhance potency, selectivity, and pharmacokinetic properties for improved anti-tumor activity. The study provides strong preclinical evidence that selective SMARCA2 degraders could be an effective therapy for SMARCA4-mutant cancers. The compounds highlight the ability of targeted protein degradation to overcome the challenges of selectively targeting SMARCA2, and offer tools for further exploration of SMARCA2-dependent tumor biology in SMARCA4 mutated cancers, marking a significant advance in precision cancer therapeutics.

To read the article’s abstract authored by Zhenwu Li et al., please visit:

<https://doi.org/10.1021/acs.jmedchem.4c01878>

###

**About SK Life Science Labs**

**SK Life Science Labs**, with headquarters in King of Prussia, Pennsylvania, is a U.S. subsidiary of **SK Biopharmaceuticals Co., Ltd.**, a pioneering South Korean company in drug development and commercialization. **SK Life Science Labs** (formerly Proteovant Therapeutics) exploits the ubiquitin-protease system (UPS) to discover and develop transformative medicines for the treatment of patients with life-altering diseases. Protein degradation harnesses the human body’s innate cellular machinery by way of the UPS to identify and mark disease-causing proteins for destruction. This promising approach provides the opportunity to target proteins of interest, many of which were previously considered

undruggable. SK Life Science Labs integrates its AI-enabled target ID platform, degrader drug-hunting expertise, and MOPED™ molecular glue screening platform to advance novel protein degraders. For more information, please visit [www.skslabs.com](http://www.skslabs.com).

**About SK Biopharmaceuticals Co., Ltd.**

SK Biopharmaceuticals Co., Ltd. is part of SK Group, South Korea's second-largest conglomerate. SK Group is a collection of global industry-leading companies driving innovations in energy, advanced materials, biopharmaceuticals and digital business. For more information about SK Biopharmaceuticals, visit [www.skbp.com/eng](http://www.skbp.com/eng).

**SK Biopharmaceuticals Co., Ltd.** is part of **SK Group**, South Korea's second-largest conglomerate. **SK Group** is a collection of global industry-leading companies driving innovations in energy, advanced materials, biopharmaceuticals and digital business. Based in Seoul, **SK Group** invests in building sustainable businesses around the world with a shared commitment to reducing global greenhouse gas emissions. **SK Group** companies combined have \$151 billion in global annual revenue and employ more than 100,000 people worldwide. SK Group is one of TIME's 100 Most Influential Companies of 2023. **SK Inc.**, the parent company of SK Biopharmaceuticals, continues to enhance its portfolio value by executing long-term investments with a number of competitive subsidiaries in various business areas, including pharmaceuticals and life science, energy and chemicals, information and telecommunication, and semiconductors. In addition, **SK Inc.** is focused on reinforcing its growth foundations through profitable and practical management based on financial stability, while raising its enterprise value by investing in new future growth businesses. For more information about **SK Inc.**, visit <https://sk-inc.com/en/main/mainpage.aspx>. For more information about **SK Biopharmaceuticals**, visit [www.skbp.com/eng](http://www.skbp.com/eng).

**SK Life Science Labs**

Dina Albanese

[Media@SKLSLabs.com](mailto:Media@SKLSLabs.com)